Companies · Biotechnology

Kyttaro Ltd

LONDON · Biotechnology

Diligence memoA one-page analyst read on Kyttaro Ltd — recommendation, valuation, rhythm, risks.
$5.2M
Total raised · real
3
Rounds
1.4×
Latest step-up
Top 56%
Sector rank · raised
Seed
Latest stage · inferred · Wed May 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Kyttaro Ltd looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 3.20× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Kyttaro Ltd is one of 4291 Biotechnology companies tracked from LONDON. By capital raised it ranks mid-pack (ahead of 45% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
27
Investors (latest)
2021
Year incorporated
2022-05-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2021-03-31 Raised $276K (real) Modeled valuation $9.6M (est)$276K$9.6MPre-Seed2021Seed · 2021-05-28 Raised $2.1M (real) Modeled valuation $56M (est)$2.1M$56MSeed2021Seed · 2022-05-11 Raised $2.9M (real) Modeled valuation $45M (est)$2.9M$45MSeed2022+$2.1M+$2.9MCumulative $5.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$276K · 2021
Seed$2.1M · 2021
Seed extension$2.9M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$45.5M
Base estimate est.
$2.1M
Conservative case
$215.7M
Upside case
$14.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $9.6M · 2021-03-312021Seed · modeled $56.1M · 2021-05-28Seed · modeled $45.5M · 2022-05-112022
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
4.1 yr
Elapsed time used
4.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$4.7M/yr
Capital velocity
5.3 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.7× of median
This company$5.2M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.7× above median
This company$2.9M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$45.5M
Sector median$64.2M

Raised more than 45% of sector peers (real $). Modeled value above 43% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #12 of 207.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.6M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.3M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.6M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.8M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $56.9M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.4M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd (this company) Raised $5.2M · modeled $45.5M (est)Kyttaro Ltd
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.6M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.3M4.52×
Microbial Machines, Inc.Seed$3.9M$63.6M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.8M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$56.9M4.00×
Tekv Holdings LLCSeed$4.0M$55.4M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro Ltd this companySeed$5.2M$45.5M3.20×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$276K2021-03-31$1.5M$9.6M90%
Seed$2.1M2021-05-28$10.4M$56.1M90%
Seed$2.9M2022-05-11$14.3M$45.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$276K2021-03-31
    • First recorded raise — entered as Pre-Seed.
    • 6 investors on this round.
  2. Seed$2.1M2021-05-28
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 7.6× larger than the prior — scaling up.
    • 27 investors on this round.
  3. Seed$2.9M2022-05-11
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 27 investors on this round.
Intelligence
2022 ~Q4
Modeled next raise · ~7mo cadence
$3.9M
Modeled next size est.range $2.9M$6.3M
1.4×
Last step-up
$4.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
DOUGLAS EBY1 other2021-03
ARKADIY CHAPKO2021-03
CHAS BOUNTRA2021-03
WILLIAM STOVIN2021-03
Registry & provenance

Kyttaro Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1939863
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CAMBRIDGE SCIENCE CorpBiotechnologySeed$3.2M$98.3Mnetwork1 shared operator · same sector · same stage
Resonant Therapeutics, Inc.BiotechnologySeed$5.1M$55.2Msame sector · same stage
Nitric BioTherapeutics, Inc.BiotechnologySeed$5.5M$45.3Msame sector · same stage
Pluto Immunotherapeutics, Inc.BiotechnologySeed$5.0M$54.2Msame sector · same stage
Future Path Medical Holding Company, LLCBiotechnologySeed$5.6M$48.0Msame sector · same stage
Aegis Spine, Inc.BiotechnologySeed$5.6M$35.6Msame sector · same stage
Theralink Technologies, Inc.BiotechnologySeed$5.7M$39.7Msame sector · same stage
AvidBiotics Corp.BiotechnologySeed$4.8M$37.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Kylix Bio, Inc.BiotechnologyPre-Seed$1.5M87%
Kytopen Corp.BiotechnologySeries B$39.0M87%
Mitera Biosciences Inc.BiotechnologySeed$9.4M85%
Innara Health, Inc.BiotechnologySeed$66.3M84%
Kiniksa Pharmaceuticals, Ltd.BiotechnologySeries A$318.1M84%
Lazzaro Medical, Inc.BiotechnologySeries A$81.8M84%
Avita Medical, Ltd.BiotechnologySeries B$610.2M84%
Codetta Bio Inc.BiotechnologySeries A$68.0M83%
Frequently asked
How much funding has Kyttaro Ltd raised?
Kyttaro Ltd has raised approximately $5.2M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Kyttaro Ltd's estimated valuation?
Provath's modeled valuation for Kyttaro Ltd is approximately $45.5M (modeled range $2.1M–$215.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kyttaro Ltd at?
Kyttaro Ltd's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed May 11.
What does Kyttaro Ltd do and where is it based?
Kyttaro Ltd operates in the Biotechnology sector, based in LONDON.
Explore related

See where Kyttaro Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kyttaro Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.